I-Mab expands manufacturing for multiple myeloma antibody; Granules issued 'minor observations' after inspection
China-based biopharma I-Mab has landed a partnership with Shanghai’s Hangzhou Qiantang New Area to manufacture drugs locally and speed up the company’s path toward commercialization.
The deal will help it commercialize felzartamab, a monoclonal antibody that targets multiple myeloma, in China. Hangzhou has started operating on what it calls a Phase I site and started construction in December on an 80,000 square-meter spot for Phase II.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.